A pilot clinical study to E valuate L iraglutide-mediated A nti-platelet activity i n patients with type-2 D iabetes (ELAID study)

• Published in: Journal of diabetes and its complications 2022-05, Vol.36 (5)
• Main Authors: Jayasree Loganathan, Cohen, Adam C, Kaloupis, Georgia M, Harris, Carolyn, Chronopoulos, Andriana, James, Vanessa, Hamilton, Justin, Green, Sarah, Wallis, Andrew, Morgan, Susan, Dauer, Raymond, Gilfillan, Christopher, Dear, Anthony E
• Format: Article
• Language: English
• Subjects: Biochemistry; Blood platelets; Cardiac stress tests; Cardiovascular disease; Diabetes; Drug dosages; Laboratories; Patients; Thrombosis; Variance analysis
• ISSN: 1056-8727; 1873-460X
• DOI: 10.1016/j.jdiacomp.2022.108188

BackgroundLiraglutide is an effective treatment for the management of type 2 diabetes mellitus (T2DM). In addition to glycemic control and potential cardioprotective effects, recent studies suggest a possible role for liraglutide in the inhibition of platelet reactivity, further attenuating atherothrombotic risk in patients with T2DM. We evaluated the in-vivo antiplatelet effect of liraglutide in T2DM patients without macrovascular disease or concurrent anti-platelet therapy.MethodsA double-blind, placebo-controlled pilot study of 16 T2DM patients, 51–69 y/o, (mean age 60.4 y/o, 63.0% male) randomised to receive liraglutide (1.8 mg/day) or placebo (saline) for 6 months was conducted. Platelet aggregation studies at baseline and after initiation of the study intervention: days 1, 7, and 14 and months 1, 3 and 6 were performed.ResultsLiraglutide (n = 7) and placebo (n = 9) treated patients demonstrated normal platelet aggregation responses although transient and significant attenuation in maximum slope of platelet aggregation in response to collagen (p ≤ 0.05), arachidonic acid (p ≤ 0.05) and ADP (p ≤ 0.02) was observed in liraglutide compared to placebo treated patients in the first week.ConclusionsIn this pilot study of patients with T2DM liraglutide treatment was associated with a significant, early and transient decrease in maximum slope of platelet aggregation. The clinical significance of this effect is currently unknown and may warrant further investigation.Clinical Trial Registration Number: UTN 1111-1181-9567.